Keliximab  (Synonyms: SB-210396; IDEC CE9.1)

Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a K_i value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research^[1][2].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Chimeric

Keliximab shows a K_d value of 1.0 nM for binding with soluble CD4 (sCD4)^[2].
Keliximab (0.01-10 μg/mL; 30 min) dose-dependently binds to the CD4⁺ thymoma cell line SupT1 with an ED₅₀ of 0.2 μg/mL^[1].
Keliximab (0-1000 ng/mL) blocks T cell proliferation and IL-2 production with IC₅₀s of 10-30 ng/mL in primary human plasmablastic lymphomas (PBLs)^[1].
Keliximab (1-1000 ng/mL; 5 min) dose-dependently mediates cell-cell adhesion with an ED₅₀ value of 20 ng/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Keliximab (5-125 mg/kg; i.v., once) decreases CD4⁺ T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

174722-30-6

Liquid

Colorless to light yellow

[Keliximab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• [1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.  [Content Brief]

  [2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.  [Content Brief]